PTP1B, A Potential Target of Type 2 Diabetes Mellitus

Jia Sun1,2, Hao Gu1,2, Yanjun Wang1,2, Hui Huang1,2, Minrui Zhang1,2, Hongyan Li1,2, Yejun Zhao1,2, Yang Wang1 and Wei Zou1,2*

1College of Life Science, LiaoNing Normal University, Dalian 116081, China
2Liaoning Key Laboratories of Biotechnology and Molecular Drug Research and Development, Dalian, 116081, China

Abstract

Diabetes is one of the common metabolic diseases, mainly divided into two types, type 1 diabetes mellitus and type 2 diabetes mellitus. Insulin resistance is the main performance of type 2 diabetes mellitus which are relative to some gene mutation, genetics, obesity and so on. Protein-tyrosine phosphatase 1B (PTP1B) plays an important role as a negative regulator in insulin signaling pathways that are implicated in metabolic diseases such as obesity and type 2 diabetes. Many evidences from clinical and basic researches show that the high expression of PTP1B induces insulin resistance. It appears that PTP1B is an effective target for the treatment of type 2 diabetes mellitus. In this review, we briefly introduce composition of PTP1B and the role of PTP1B in insulin signaling of type 2 diabetes mellitus. We also summarized recent research progress of PTP1B inhibitors used in therapy of type 2 diabetes mellitus.

Keywords: PTP1B; Type 2 diabetes mellitus; Insulin signaling

Introduction

Diabetes is a common metabolic disease characterized by hyperglycemia, mainly divided into type 1 diabetes mellitus and type 2 diabetes mellitus. Insulin-dependent type 1 diabetes is mostly resulted from the damage of pancreatic β cells which makes the absolute lack of insulin; Type 2 diabetes, which is insulin independent, the main initial factors are insulin resistance (IR) and relatively lack of insulin. Due to the modern diet and genetic factors, type 2 diabetes mellitus patients have increased in recent years. O’Rahilly et al. predicted that the number of patients with type 2 diabetes mellitus will be more than 300 million by 2025, mainly in developing countries such as India [1-3]. Current treatments for type 2 diabetes mellitus are mostly dependent on insulin and some oral hypoglycemic agents. Long-term insulin injections to patients have a lot of pain and it is inconvenience. The effects of oral hypoglycemic agents are often not satisfied. Therefore, researchers are now looking for more safe and effective drugs and treatments.

The process of tyrosine phosphorylation and dephosphorylation is the basic mechanism of cell growth and differentiation, and the balance of this process was maintained by protein tyrosine phosphatase (PTP) and protein tyrosine kinase (PTK) [4]. PTPs are superfamily of receptor-like and non-transmembrane proteins, whose members are highly specific, tightly regulated and important modulators of cellular signal initiation and termination. Protein tyrosine phosphatase 1B (PTP1B) is a key member of the family, a negative regulator in insulin signal transduction [5] and a potential target for treatment of type 2 diabetes mellitus [6]. Therefore, small-molecule PTP1B inhibitors have broad application prospects in the treatment of type 2 diabetes. Here, we briefly introduce composition of PTP1B, the role of PTP1B in insulin signaling of type 2 diabetes mellitus [6]. Therefore, small-molecule PTP1B inhibitors have broad application prospects in the treatment of type 2 diabetes. Here, we briefly introduce composition of PTP1B, the role of PTP1B in insulin signaling of type 2 diabetes mellitus.

PTP1B, as a potential target for type 2 diabetes and obesity, have expanded out of PTP1B gene cDNA span [11]. At the same time, the molecular dynamics studies of interaction between PTP1B and its inhibitors are also on going [12], all which lay a foundation for screening specific PTP1B inhibitors.

The role of PTP1B in insulin signaling of type 2 diabetes mellitus

The pathogenesis of type 2 diabetes mellitus is associated with gene mutation, heredity, obesity and other factors, which main performance is insulin resistance. It appears that PTP1B is an effective target for the treatment of type 2 diabetes mellitus. In this review, we briefly introduce composition of PTP1B and the role of PTP1B in insulin signaling of type 2 diabetes mellitus.
resistance. Dysfunction of pancreatic β cells is one of basic processes and characteristic of the pathogenesis. The increased prevalence of these diseases highlights the urgent need to elucidate the underlying molecular mechanisms to aid in therapeutic intervention.

Insulin secreted from pancreatic β cells acts as a major regulator of glucose homeostasis through a complex and integrated signaling network. Insulin receptor is a kind of transmembrane glycoprotein complex molecules, consisting of two alpha and beta subunits by three disulfide bond connection, among which the alpha subunits locate in the lateral of the cell and beta subunits are across the cell membrane. Insulin binding alpha subunits of the receptor induced phosphorylation of tyrosine residues and protein tyrosine kinase (PTK) of beta subunits, and resulted in a series of phosphorylation and dephosphorylation cascade reactions including mitogen-activated protein kinases (MAPK) and PI3K/Akt signal pathways to regulate metabolism. Whereas, when the concentration of insulin is beyond the physiological concentration (hyperinsulinemia), insulin promoted cell proliferation and developments, which may due to the combination of insulin with insulin-like growth factor 1 receptor (IGF-1R) or insulin-like growth factor 1 (IGF-1) hybrid insulin receptor, and had nothing with insulin receptor [13].

Many reports indicate that PTP1B is an established metabolic regulation in mammals and a pharmacological target for type 2 diabetes. During the combination of insulin and its receptor, PTP1B could catalyze insulin receptor (IR) and insulin receptor substrates (IRS) dephosphorylation, coordinated the balance between phosphorylation and dephosphorylation of tyrosine residues, which resulted in downregulation of insulin signal transduction [14]. Besides, PTP1B could dephosphorylate activated JAK2 and STAT3, and prevented leptin signal transduction [15] (Figure 1). High expression of PTP1B influenced the activity of PTKs, which resulted in insulin failing to combine with IR, induced the insulin resistance and leptin resistance, and caused type 2 diabetes and obesity [16,17]. Zabolotny et al. found that, the phosphorylation of insulin receptor tyrosine stimulated by insulin descend by 35%, the activity of PI3K decreased 40-60% and the activity of protein kinase C (PKC) that glucose transport required also decreased in overexpressed PTP1B mice muscle compared with the normal mice [18]. Whole-body PTP1B knockout (KO) mice exhibit increased insulin sensitivity and enhanced glucose tolerance [19,20]. There is a relationship between occurrence of type 2 diabetes and abnormality lipid metabolism. So far, lots of evidences have confirmed a causal relationship between obesity and insulin resistance in humans and animals. With weight increased, insulin sensitivity and general glucose tolerance decreased [18]. Subsequent studies using tissue-specific knockout mice indicated that body weight, adiposity and leptin action were regulated by neuronal PTP1B. Neuronal PTP1B deficient mice have reduced weight, adiposity, increased activity and energy consumption [21]. It has also been reported that neuronal PTP1B inhibition results in decreased hypothalamic AMP-activated protein kinase (AMPK) activity in peripheral tissues and downstream gene expression changes that promote leanness and increased energy consumption. The mechanism by which PTP1B regulates adiposity and leptin sensitivity is likely to involve the coordinated regulation of AMPK in hypothalamus and peripheral tissues [22]. These results demonstrated a direct role of PTP1B in down regulating the insulin and leptin functioning. These findings sparked interest in developing PTP1B inhibitors for the treatment of type 2 diabetes. Therefore, PTP1B could be used as a potential drug target [23] and provide a new approach for the treatment of type 2 diabetes.

Insulin receptor mediated signal transduction, and participated in a series of cascade reactions in which protein kinase and phosphatase involved, whereas more hypoglycemic targets compounds are associated with insulin signal transduction [24]. They may function by insulin receptor, CytPTK, MAPK, S6 kinases, G protein and cAMP signaling pathway [25]. PTP1B, a member of PTP family, its main function is dephosphorylating the phosphorylated tyrosine residues, insulin receptor and insulin receptor substrates to negative regulate

![Figure 1: The physiological signal pathways involving PTP1B.](image-url)
insulin signal transduction. Therefore, PTP1B inhibitors enhance insulin signaling [26,27].

**PTP1B inhibitors and therapy of Type 2 diabetes**

PTP1B is an intracellular PTP, involved in negative regulation of insulin as well as leptin signaling. PTP1B has emerged as a validated therapeutic target for the treatment of type 2 diabetes and related metabolic abnormalities [28]. PTP1B has been inhibited experimentally using a variety of mechanisms and chemical entities. PTP1B inhibitors could potentially improve insulin resistance and normalize plasma glucose and insulin level without inducing hypoglycemia [29].

**Synthetic PTP1B inhibitor and therapy of Type 2 diabetes:**

Recent years, many pharmaceutical companies have developed various PTP1B inhibitors as drug candidates for therapy of Type 2 diabetes in clinical trials, including etiprotafib, ISIS 113715, ISIS-PTP1BRx and trodusquemine [30]. In addition, some new synthetic PTP1B inhibitors were reported such as Benzo furan and benzothiophene biphenyls, Vanadium complexes and Aminobenzoic acid.

Thiazolidinediones (TZDs) are commonly known as glitazones that share a common molecular scaffold 2, 4-TZDs. Compound 28 discovered by Koyama et al. exhibited comparable levels of glucose correction to rosiglitazone in db/db mouse type 2 diabetes animal model (Figure 2A) [31]. In addition, TZDs could correct hyperglycemia by enhancing insulin sensitivity in target tissues and were shown to improve glycemic control by ameliorating insulin resistance in both peripheral tissues and liver in type 2 diabetic patients [32]. Clinical research showed that metformin therapy in patients with type 2 diabetes combined with TZDs could reduce the risk of treatment failure [33]. TZDs lower glycosylated hemoglobin (HbA1c) levels more effectively than GLP-1 mimetics or dipeptidyl peptidase IV (DPP IV) inhibitors and achieve greater durability than biguanides [34]. However, the side effect and safety profiles of peroxisome proliferator-activated receptor-γ (PPAR-γ) as a class have come into question [35]. The marketing of TZDs was severely restricted in 2011 [36].

Mimetics of pTyr are starting points for the design of competitive PTP1B inhibitors, containing a carboxylic or phosphonic acid and a large lipophilic tail. Rakse et al. reported a novel 3-acetamido-4-methyl benzoic acid derivatives as pTyr mimetics, the most potent compound 10 showed PTP1B predominantly inhibited activity (Figure 2B) [37,38].

Figure 2: Chemical structures of several synthetic PTP1B inhibitors.
Natural molecules as PTP1B inhibitor and therapy of Type 2 diabetes: Creatures of nature synthesized a variety of novel structure and secondary metabolites during biological evolution. Secondary metabolites contain structural diversity and kind medicinal properties and many drugs are directly or indirectly derived from natural products. What's more, secondary metabolites will continue to serve as new drugs. Therefore, natural products are considered as important sources for new drugs for PTP1B inhibitors [51]. A wide variety of natural products have been reported with PTP1B inhibitory activity such as Morphinane alkaloid, Flavonoid, Terpenoids and so on.

Morphinane alkaloid, a kind of nitrogenous alkaline organic compound and an effective ingredient in alkaloids, is important active component in Chinese herbal medicine which widely exists in nature. It was demonstrated that berberineome, papaverine and flavonoid are all effective anti-diabetic herb through inhibiting PTP1B [52,53] and significantly reducing the fasting blood glucose levels [54]. Flavonoid isolated from Glycyrrhiza inflata, Cyclocarya paliurus and Pongamia pinnata can also inhibit PTP1B activities (Figures 3A-3C) [55,56]. Terpenoids as organic compounds distribute in plants, animals and marine life, significantly inhibited the activity of PTP1B (PTP1B) (Figures 3D and 3E) [57-60]. In addition, PTP1B inhibitory activity were also shown in proteoglycan, quinolone, steroids, containing nitrogen or sulfur compounds for anti-diabetes [61-63].

In summary, it was found that PTP1B is the critical negative regulator in insulin signaling pathway, and plays an important role in the pathogenesis of type 2 diabetes mellitus. The development of small-molecule drugs for PTP1B (obtained from herb or synthetic) maybe has a good future for the treatment of type 2 diabetes mellitus [64,65].

Acknowledgement
This project was supported by the National Natural Science Foundation of China (No. 30970353) and Science and Technology Plan Projects in Liaoning Province, China (No. 2015020568).

References


